Drug Trial Radar · NCT03070470
CiPA Phase 1 ECG Biomarker Validation Study
Last checked: Nov 20, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Mar 14, 2017
Primary completion
Jun 26, 2017
Study completion Jun 26, 2017
Sponsor
- Lead sponsor
- Food and Drug Administration (FDA)Federal agency
- Sponsor type
- Federal agency
- Collaborators
- Spaulding Clinical Research LLC
- First posted
- Mar 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess whether exposure response analysis of the electrocardiographic QTc and J-Tpeakc intervals in Phase 1 clinical pharmacology studies can be used to confirm that drugs that predominantly block the potassium channel encoded by the human ether-à-go-go-related gene (hERG) with approximately equipotent late sodium and/or calcium block ("balanced ion channel" drugs) do not cause J-Tpeakc prolongation and that drugs that predominantly block hERG without late sodium or L-type calcium current block ("predominant hERG" drugs) cause QTc prolongation.
Conditions
- Drug-induced QT Prolongation
- Pharmacokinetics
- Pharmacodynamics
Interventions
RanolazineDrug
Ranolazine 1500 mg orally two times per day for 2.5 days
VerapamilDrug
Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
Lopinavir / RitonavirDrug
Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
ChloroquineDrug
Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
PlaceboDrug
Placebo (administered orally)
Dofetilide and DiltiazemDrug
In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)Time frame: 3 days
- Change From Baseline QTc With "Predominant hERG" Blocking Drug (Chloroquine)Time frame: 3 days
- QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)Time frame: 3 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spaulding Clinical Research
West Bend, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.